Pretomanid
Sponsors
Assistance Publique Hopitaux De Paris, National Institute of Allergy and Infectious Diseases (NIAID), Medecins Sans Frontieres, Netherlands, Global Alliance for TB Drug Development, Tuberculosis Research Centre, India
Conditions
Drug Sensitive TuberculosisDrug-Resistant TuberculosisExtensively Drug-Resistant TuberculosisHIV InfectionsMulti-drug Resistant TuberculosisMultidrug Resistant TuberculosisNon-responsive Multidrug-Resistant Pulmonary TBPatients diagnosed at the study sites with rifampicinresistant
tuberculosis during the recruitment period will be evaluated
for study inclusion.
Phase 1
Single-dose Study in Two Panels of Healthy Adult Participants to Assess Immediate-Release and Dispersible Formulations of Pretomanid
CompletedNCT04309656
Start: 2020-01-14End: 2020-02-28Updated: 2024-07-24
Study of a Single Dose of Pretomanid Added to an Optimized Background Regimen in Children With Rifampicin-Resistant Tuberculosis
RecruitingNCT05586230
Start: 2023-10-03End: 2026-05-02Target: 72Updated: 2026-03-23
Phase 2
Pragmatic Clinical Trial for a More Effective Concise and Less Toxic MDR-TB Treatment Regimen(s)
CompletedNCT02589782
Start: 2017-01-31End: 2022-08-05Updated: 2024-05-01
Trial to Evaluate the Efficacy, Safety and Tolerability of BPaMZ in Drug-Sensitive (DS-TB) Adult Patients and Drug-Resistant (DR-TB) Adult Patients
CompletedNCT03338621
Start: 2018-07-30End: 2022-06-10Updated: 2024-03-07
PRACTECAL-PKPD Sub Study
NCT04081077
Start: 2019-08-06End: 2022-09-30Target: 240Updated: 2021-05-14
A Trial to Evaluate the Male Reproductive Safety of Pretomanid in Adult Male Participants With Drug Resistant Pulmonary Tuberculosis
CompletedNCT04179500
Start: 2021-09-16End: 2024-07-17Updated: 2025-01-17
Economic Evaluation of New MDR TB Regimens
CompletedNCT04207112
Start: 2020-10-20End: 2022-08-25Updated: 2024-04-22
A Pan-TB Regimen Targeting Host and Microbe
Active, not recruitingNCT05686356
Start: 2023-07-28End: 2026-01-31Target: 352Updated: 2025-05-28
Phase 2 Trial Assessing TBAJ876 or Bedaquiline, with Pretomanid and Linezolid in Adults with Drug-sensitive Pulmonary Tuberculosis
Active, not recruitingNCT06058299
Start: 2023-10-24End: 2026-06-30Updated: 2025-02-17
Trial of Novel Regimens for the Treatment of Pulmonary Tuberculosis
RecruitingNCT06192160
Start: 2025-03-11End: 2027-08-11Target: 315Updated: 2026-03-19
Program for Rifampicin-Resistant Disease With Stratified Medicine for Tuberculosis
RecruitingNCT06441006
Start: 2025-10-03End: 2031-08-01Target: 400Updated: 2026-01-20
Phase 3
Various Doses and Durations of Linezolid Plus Bedaquiline & Pretomanid in Participants With Drug Resistant Tuberculosis
CompletedNCT03086486
Start: 2017-11-21End: 2022-02-08Updated: 2023-06-29
Modified BPaL Regimen for Managing Pre-XDR TB and MDR (TI/NR) TB in India
NCT05040126
Start: 2021-10-07End: 2024-12-31Target: 400Updated: 2024-01-03
Feasibility of the Application of a new Six-month Treatment for multidrug-resistant tuberculosis (MDR-TB) patients in France (FAST-MDR)
Not yet recruitingCTIS2024-512763-32-00
Target: 50Updated: 2025-07-31
Unknown Phase
Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy
CompletedNCT00042289
Start: 2003-06-09End: 2020-09-30Updated: 2025-12-02
Patient-reported Experiences and Quality of Life Outcomes in the TB-PRACTECAL Clinical Trial
CompletedNCT03942354
Start: 2019-09-01End: 2022-05-10Updated: 2024-05-29
Related Papers
11 more papers not shown